Impact of a pilot mHealth intervention on treatment outcomes of TB patients seeking care in the private sector using Propensity Scores Matching-Evidence collated from New Delhi, India

PLOS Digit Health. 2024 Sep 11;3(9):e0000421. doi: 10.1371/journal.pdig.0000421. eCollection 2024 Sep.

Abstract

Mobile health applications called Digital Adherence Technologies (DATs), are increasingly used for improving treatment adherence among Tuberculosis patients to attain cure, and/or other chronic diseases requiring long-term and complex medication regimens. These DATs are found to be useful in resource-limited settings because of their cost efficiency in reaching out to vulnerable groups (providing pill and clinic visit reminders, relevant health information, and motivational messages) or those staying in remote or rural areas. Despite their growing ubiquity, there is very limited evidence on how DATs improve healthcare outcomes. We analyzed the uptake of DATs in an urban setting (DS-DOST, powered by Connect for LifeTM, Johnson & Johnson) among different patient groups accessing TB services in New Delhi, India, and subsequently assessed its impact in improving patient engagement and treatment outcomes. This study aims to understand the uptake patterns of a digital adherence technology and its impact in improving follow-ups and treatment outcomes among TB patients. Propensity choice modelling was used to create balanced treated and untreated patient datasets, before applying simple ordinary least square and logistic regression methods to estimate the causal impact of the intervention on the number of follow-ups made with the patient and treatment outcomes. After controlling for potential confounders, it was found that patients who installed and utilized DS-DOST application received an average of 6.4 (95% C.I. [5.32 to 7.557]) additional follow-ups, relative to those who did not utilize the application. This translates to a 58% increase. They also had a 245% higher likelihood of treatment success (Odds ratio: 3.458; 95% C.I. [1.709 to 6.996]).

Grants and funding

The study was partially sponsored by Johnson & Johnson Global Public Health, which provided a grant to TB Alert India to implement the CfL pilot in three private facilities in New Delhi, India. This pilot, nested within the larger JEET project funded by The Global Fund and managed by WJCF, formed the basis of this research. TB Alert India, a sub-recipient of WJCF, was responsible for data acquisition. The study was conceived jointly by WJCF, J&J, and TB Alert India. Johnson & Johnson did not fund WJCF or the affiliated authors, who conducted the data analysis and manuscript preparation. Specifically, RS, VV, and AP received no funding for this study. TP and JW, as J&J employees, contributed as part of their regular duties. VP and KS, employees of TB Alert India, were partially funded by the J&J grant for programmatic operations but received no additional funding for the research or manuscript. Johnson & Johnson Global Public Health, through TP and JW, contributed to study design, the decision to publish, and manuscript preparation but did not participate in data collection or analysis.